Celcuity

IPO

Celcuity Block Pam. Unlock Tomorrow

Public · Minneapolis, United States · Founded 2011 · $550.1M raised

Employees
51–200
Founded
2011
Business Model
B2B
Total Funding
$550.1M
Last Round
$286.5M Convertible NoteAug 2025
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Celcuity is a clinical-stage biotechnology company developing molecularly targeted therapies for solid tumor cancers driven by PI3K pathway dysregulation. Its lead candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials for HR+/HER2- advanced breast cancer and has received an FDA NDA acceptance. The company also develops companion diagnostics to identify patients most likely to benefit from its precision oncology therapies.

Summary

Celcuity is a Biotech company based in Minneapolis, United States, founded in 2011. It has raised $550.1M in total across 5 rounds, most recently a $286.5M Convertible Note round in Aug 2025. Investors include New Enterprise Associates and Deerfield Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

ConvertibleConvertible NoteAug 2025
$286.5M

Sign up to see all 5 events

Funding: Series A through Convertible Note. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Celcuity on Indexed.vc
<a href="https://indexed.vc/companies/celcuity"><img src="https://indexed.vc/api/badge/company/celcuity" alt="Celcuity on Indexed.vc" width="260" height="76" /></a>